BACKGROUND
==========

Invasive mold infections (IMI) represent a major cause of morbidity and mortality among pediatric patients affected by hematological malignancies and are often associated with poor clinical outcomes despite the use of active antifungal drugs \[[@R1]-[@R6]\].

Controversies exist over the benefit of using a combination antifungal treatment (CAT) in this patient population. In particular, the attempt of improving the efficacy of the treatment is often balanced by concerns of a decreased safety due to cumulative toxicities. Evidence about the role of CAT for the treatment of IMI is scarce in the adult population and even more limited in the pediatric setting. In particular, well-designed studies on the use of CAT in immunocompromised children are lacking, and the current knowledge on this topic mainly relies on retrospective and prospective cohorts \[[@R1]-[@R6]\]. In this scenario, any experience of treating IMI with CAT in children may help clinicians to gain knowledge in this field and hopefully serve as a starting point for further larger studies. Hence, we report our real-life case series on the use of CAT in the pediatric setting.

METHODS
=======

We present a case series of IMI in children affected by hematological malignancies treated with CAT at the Hematology-Oncology and Bone Marrow Transplantation Unit, Pediatric Department, San Gerardo Hospital, Monza, Italy, from 2011 to 2016, with the aim of describing their clinical characteristics, types of infections, clinical outcomes, and treatment safety.

All patients with diagnosis of possible, probable, or proven IMI as defined by the European Organization for Research and Treatment of Cancer (EORTC) criteria were included \[[@R7]\]. Medical records were retrospectively reviewed to describe patients\' characteristics, outcomes, and treatment safety.

For each patient we recorded the clinical outcome 12 weeks after diagnosis of IMI: among living patients we distinguished those with complete response to treatment (full recovery) and those with partial response (major improvement of symptoms and radiologic findings).

RESULTS
=======

During the study period (2011-2016) 13 cases of IMI in pediatric patients affected by hematological malignancies were treated with CAT at our Center. Eight of 13 patients (61.5%) were males and the mean age was 10 years (3 months-16 years) For demographic characteristics of patients see [Table 1](#T1){ref-type="table"}.

###### 

Demographics and characteristics of hematological malignancies of 13 patients with invasive mold infections

  Patient   Gender and Age (years)   Ethnicity   Haematological Disease   Time of Occurrence   Haematological Treatment   Neutropenia (N/mm^3^)   GVHD   Steroid (prednisone equivalent)
  --------- ------------------------ ----------- ------------------------ -------------------- -------------------------- ----------------------- ------ ---------------------------------
  1         M, 9                     White       Relapsed ALL             Induction Therapy    CT                         \< 100                  No     \> 2 mg/kg day
  2         M, 14                    White       Relapsed ALL             allo-SCT (day+10)    CyA, MTX, ATG              \< 100                  No     No
  3         F, 5                     White       ALL front line           Induction Therapy    CT                         \< 500                  No     \> 2 mg/kg day
  4         F, 8                     White       ALL front line           Induction Therapy    CT                         \< 100                  No     \> 2 mg/kg day
  5         M, 13                    White       ALL front line           Induction Therapy    CT                         \< 100                  No     \> 2 mg/kg day
  6         M, 16                    White       ALL front line           Induction Ttherapy   CT                         \> 500                  No     \> 2 mg/kg day
  7         M, 12                    White       NHL                      relapse/salvage      CT                         \<100                   No     \> 2 mg/kg day
  8         F, 3                     White       Relapsed ALL             relapse/salvage      CT                         \< 100                  No     \< 2 mg/kg day
  9         M, 15                    White       Relapsed AML             relapse/salvage      CT                         \< 100                  No     \> 2 mg/kg day
  10        M, 16                    Asian       CML                      allo-SCT (day+200)   MMF, PDN                   500-1000                Yes    \> 2 mg/kg day
  11        F, 12                    White       ALL front line           Induction Therapy    CT                         \< 100                  No     \> 2 mg/kg day
  12        M, 10                    Asian       Relapsed NHL             allo-SCT (day+120)   CyA, PDN                   \< 500                  No     \< 2 mg/kg day
  13        F, 90 days               African     HLH                      Induction Therapy    DXM, VP16, ATG             \< 500                  No     \> 2 mg/kg day

Abbreviations: M = Male; F = Female; ALL = Acute Lymphoid Leukemia; NHL = Non-Hodgkin Lymphoma; AML = Acute Myeloid Leukemia; CML = chronic myeloid leukemia; HLH = haemophagocitic hystiocitosis; SCT = Stem Cells Transplantation; CyA = Cyclosporine A; MTX = methotrexate; ATG = anti-thymocyte globulin; CT = Chemotherapy; MMF = mycofenolate mofetil; PDN = prednisone; DXM = dexamethasone; VP16 = etoposide; N = neutrophils; GVHD = Graft Versus Host Disease

Invasive Mold Infections and Disease Site Involvement
-----------------------------------------------------

Five patients (38.5%) met EORTC criteria for proven IMI. In particular, *Absidia Corymbifera* and another untyped Mucorales grew on the orbital biopsies of 2 patients with rhino-orbital-cerebral mucormycosis while *Aspergillus flavus* grew on the orbital biopsy of 1 patient with rhino-cerebral and pulmonary aspergillosis; *Fusarium subglutinans* was isolated from blood cultures of a fourth patient with disseminated fusariosis with cutaneous involvement. A fifth patient had hyphae on a liver biopsy establishing the diagnosis of proven IMI, probable Aspergillosis (no results from cultures were available) with hepatosplenic and pulmonary involvement.

Five more patients had probable pulmonary aspergillosis, documented by Galactomannan antigen assay and compatible clinical-radiological signs. These patients all had pulmonary disease with 3 of them also having central nervous system (CNS) involvement and 1 having liver involvement.

The remaining 3 patients had possible pulmonary aspergillosis with 1 also having hepatosplenic involvement.

Of note, the diagnosis of probable or possible hepatosplenic involvement was established by imaging. Characteristics of IMI are summarised in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics of invasive mold infections (IMI) and patients\' outcome.

  Patient   EORTC Classification                  Species                 Site of IMI             Concurrent Infections         Combination Therapy    Outcome and 12-weeks Response
  --------- ------------------------------------- ----------------------- ----------------------- ----------------------------- ---------------------- -------------------------------
  1         Possible aspergillosis                \-                      lung, liver, spleen     coronavirus 229E/NL63         L-AMB + caspofungin    Favourable (CR)
  2         Probable aspergillosis                \-                      lung                    BSI S.mitis/R. mucilaginosa   L-AMB + caspofungin    Favourable (PR)
  3         Probable aspergillosis                \-                      lung, CNS               RSV B                         L-AMB + voriconazole   Failure, death due to IMI
  4         Proven IMI (probable aspergillosis)   \-                      lung, liver, spleen     No                            L-AMB + caspofungin    Favourable (CR)
  5         Probable aspergillosis                \-                      lung, CNS, liver        BSI S. Epidermidis            L-AMB + voriconazole   Favourable (PR)
  6         Proven mucormycosis                   Absidia corymbifera     rinocerebral            No                            L-AMB + posaconazole   Favourable (CR)
  7         Proven mucormycosis                   Untyped mucorales       rhino-orbito-cerebral   No                            L-AMB + posaconazole   Favourable (CR)
  8         Proven fusariosis                     Fusarium subglutinans   BSI, skin               rinovirus A/B/C               L-AMB + voriconazole   Favourable (CR)
  9         Possible aspergillosis                \-                      lung                    No                            L-AMB + posaconazole   Failure, death due to HD
  10        Probable aspergillosis                \-                      lung, CNS               CMV viremia                   L-AMB + voriconazole   Failure, death due to IMI
  11        Probable aspergillosis                \-                      lung                    BSI P. aeruginosa             L-AMB + caspofungin    Favourable (PR)
  12        Possible aspergillosis                \-                      lung                    VZV Zoster C5-C7              L-AMB + voriconazole   Favourable (CR)
  13        Proven aspergillosis                  Aspergillus flavus      lung, rhinocerebral     K.pneumoniae UTI              L-AMB + caspofungin    Failure, death due to HD

Abbreviations: EORTC: European Organization for Research and Treatment of Cancer IMI = Invasive Mold Infections; CNS = Central Nervous System; BSI = Bloodstream Infection; RSV = Respiratory Syncitial Virus; CMV = Cytomegalovirus; VZV = Varicella Zoster Virus; UTI = Urinary Tract Infection; L-AMB = liposomal amphotericin B; CR = Complete Response; PR = Partial Response; HD = Hematological Disease.

Hematological Malignancies
--------------------------

Ten patients developed IMI while receiving chemotherapy and 3 following hematopoietic stem cell transplantation (HSCT).

Among patients receiving chemotherapy, 7/10 were affected by acute lymphoblastic leukemia (ALL) (of whom 5 in front-line therapy and 2 in first-relapse), 1/10 was affected by first-relapsed acute myeloid leukemia (AML), 1/10 by first-relapsed non-Hodgkin lymphoma (NHL) and 1/10 by haemophagocitic lymphohistiocytosis (HLH) in front-line treatment.

All were in the most intensive phases of chemotherapy (6 in the induction and 4 in the re-induction phase), essentially with anthracyclines, vincristine, steroids, antimetabolites, and alkylating agents.

In the second group patients received HSCT for relapsed NHL, relapsed ALL, and chronic myeloid leukemia. All of them received a myeloablative conditioning regimen. One patient had liver graft-versus-host-disease and was receiving treatment with cyclosporine, mycophenolate, and steroids.

All patients were neutropenic at the time of the diagnosis of IMI: in particular 8/13 patients (62%) had neutrophil count \< 100/μL, 3/13 patients (23%) had neutrophil count within 100-500/μL and 2/13 patients within 501-1000/μL. Severe neutropenia (defined as neutrophil count \< 500/mm^3^) preceding the diagnosis of IMI lasted on average 10.9 days (5-26 days).

Moreover, 12/13 patients were receiving steroids (7 prednisolone, 2 dexamethasone, 3 methylprednisolone), of whom 83% were receiving high doses (prednisone equivalent \> 2mg/Kg/daily). All transplanted patients were also undergoing prophylaxis with cyclosporine. According to internal guidelines, 7/13 patients were receiving antifungal prophylaxis for high-risk underlying disease, 4 with liposomal amphotericin (L-AMB), 2 with fluconazole, one with posaconazole. Characteristics of hematological malignancies are summarised in [Table 1](#T1){ref-type="table"}

Treatment
---------

Ten out of 13 patients received CAT as salvage treatment while the remaining 3/13 received CAT as first-line approach: in the latter group, 2 were undergoing prophylaxis with L-AMB twice/weekly and one with fluconazole (6-10 mg/Kg/daily) when diagnosis of IMI was established.

Combination regimens included L-AMB associated with caspofungin (5/13, 38.4%), posaconazole (3/13, 23.1%), and voriconazole (5/13, 38.4%). Ten patients received L-AMB at 3-5 mg/Kg/daily while 3 patients with CNS involvement received 5-10 mg/Kg/daily. Caspofungin was used at the dosage of 50 mg/m2/daily while the dosage of posaconazole and voriconazole was titrated according to their plasmatic concentrations (Therapeutic Drug Monitoring, TDM). Caspofungin was chosen as the second antifungal agent in 5 patients with invasive aspergillosis (IA), while posaconazole was given to 2 patients with rhino-orbital-cerebral mucormycosis, and to 1 patient with possible IA who was already receiving L-AMB prophylaxis.; voriconazole was chosen as the second agent in 3 patients with CNS aspergillosis, in 1 patient with pulmonary aspergillosis and in 1 patient with invasive fusariosis. The mean duration of CAT was 40 days (5-98 days). Maxillo-facial surgery was required in cases of rhino-orbital-cerebral mucormycosis and aspergillosis. For treatment see [Table 3](#T3){ref-type="table"}.

###### 

Combination antifungal therapy regimens.

  Patient   Monotherapy Before Combination   Duration of Monotherapy (Days)   Combination Therapy    Duration of Combination Therapy (Days)   Maintainance Therapy                                                 Duration of Maintainance Therapy (Months)   Surgery
  --------- -------------------------------- -------------------------------- ---------------------- ---------------------------------------- -------------------------------------------------------------------- ------------------------------------------- ---------
  1         L-AMB                            11                               L-AMB + caspofungin    37                                       Voriconazole; L-AMB posaconazole^[§](#TF3-2){ref-type="table-fn"}^   12                                          No
  2         L-AMB                            12                               L-AMB + caspofungin    48                                       L-AMB                                                                \> 18                                       No
  3         L-AMB                            2                                L-AMB + voriconazole   11                                       \[NA\]                                                               \[NA\]                                      No
  4         L-AMB                            21                               L-AMB + caspofungin    41                                       Voriconazole                                                         10                                          No
  5         L-AMB                            11                               L-AMB + voriconazole   49                                       Voriconazole                                                         15                                          No
  6         voriconazole                     3                                L-AMB + posaconazole   92                                       Posaconazole                                                         48                                          Yes
  7         L-AMB                            12                               L-AMB + posaconazole   98                                       L-AMB posaconazole^[§](#TF3-2){ref-type="table-fn"}^                 4                                           Yes
  8         L-AMB                            6                                L-AMB + voriconazole   10                                       Voriconazole                                                         1, 5                                        No
  9         No                               \-                               L-AMB + posaconazole   28                                       \[NA\]                                                               \[NA\]                                      No
  10        No                               \-                               L-AMB + voriconazole   5                                        \[NA\]                                                               \[NA\]                                      No
  11        No                               \-                               L-AMB + caspofungin    36                                       Voriconazole                                                         12                                          No
  12        L-AMB                            24                               L-AMB + voriconazole   17                                       Voriconazole                                                         48                                          No
  13        L-AMB                            unknown                          L-AMB + caspofungin    50                                       \[NA\]                                                               \[NA\]                                      Yes

(\*) Including laboratory investigations

consecutive regimens

Abbreviations: L-AMB = liposomal amphotericin B; NA = Non Applicable.

Outcome
-------

We recorded the outcome 12 weeks after the diagnosis of IMI. Overall mortality was 30.7% (4/13). Two deaths were related to progression of CNS aspergillosis and 2 to progression of the underlying malignancy. The 12-week overall response was 69.2%: 6 patients showed complete response (one reporting monocular blindness after surgical curettage of the orbit), while 3 showed partial response (see [Table 2](#T2){ref-type="table"}).

Safety
------

Toxicities during CAT were classified according to Common Terminology Criteria for Adverse Events \[[@R8]\]. Overall, CAT was well tolerated. Seven patients reported transitory altered liver tests, including bilirubin, transaminases, and gamma-glutamyltransferase (GGT). In particular 2 patients reported a grade 1 increase of liver markers (both of GGT and one of transaminases), 2 patients reported a grade 2 increase of bilirubin with 1 of them also reporting a grade 2 increase of GGT and the other reporting a grade 2 increase of transaminases. The remaining 3 patients reported a grade 3 increase of GGT with 2 of them also reporting a grade 3 increase of transaminases.

Moreover, 6 patients reported acute kidney injury (AKI) and 6 hypokalemia. Markers of liver dysfunction were high in 4 patients treated with the combination L-AMB + voriconazole and in 3 patients treated with the combination L-AMB + caspofungin, of note, among these patients 2 also had hepatic involvement by the fungal infection.

In 1 case AKI led to L-AMB dose reduction, in another patient altered liver tests led to temporary discontinuation of CAT that was safely reintroduced 24 hours later, after improvement of the hepatic function. No definitive discontinuation occurred (see [Table 4](#T4){ref-type="table"}).

###### 

Toxicities attributed to combination antifungal therapy.

  Patient   Hepatobiliary Toxicity\*      Renal Toxicity\*                  Treatment Discontinuation or Modification
  --------- ----------------------------- --------------------------------- -------------------------------------------
  1         Liver test increase grade 2                                     
  2         Liver test increase grade 3   AKI grade 1                       
  3         Liver test increase grade 3                                     CAT temporary discontinuation (24 hours)
  4         Liver test increase grade 3   Hypokalemia grade 2               
  5                                       AKI grade 2 Hypokalemia grade 2   
  6                                       AKI grade 2                       
  7         Liver test increase grade 2   AKI grade 2                       L-AMB dose reduction
  8                                       Hypokalemia grade 2               
  9         Liver test increase grade 1   Hypokalemia grade 2               
  10                                      AKI grade 1 Hypokalemia grade 2   
  11                                      Hypokalemia grade 2               
  12        Liver test increase grade 1   AKI grade 1                       
  13                                                                        

Abbreviations: L-AMB = liposomal amphotericin B; AKI = Acute Kidney Injury; CAT = combination antifungal therapy.

DISCUSSION AND CONCLUSIONS
==========================

Despite an improvement in the outcome of IMI in children with hematological malignancies having been reported by recent studies compared to studies from the last few decades \[[@R9]-[@R11]\], mortality is still high in this patient population. In particular, recent studies on children with hemato-oncological disorders and IMI treated with different regimens report crude mortality rates ranging from 30% to 52.5% \[[@R1]-[@R6]\], in line with our case series, in which the overall death rate was 30.7%.

CAT is often chosen as a strategy to improve the outcome in those cases of IMI with severe clinical course: its main goal is to widen the spectrum of therapy, to lower the risk of resistance and to exploit the synergism between some drugs.

Few randomized controlled studies have been published on adult patients assessing the role of CAT compared to monotherapy in the clinical setting, and there is still very little evidence about the efficacy and safety of this approach \[[@R12]\]. If evidence is limited in the adult population, it is even scarcer in the pediatric setting.

The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines still recommend monotherapy for the majority of IMI. Combination therapy with echinocandins + L-AMB or azoles are listed as an alternative in salvage therapy for IA while the association of L-AMB with posaconazole or caspofungin is regarded as an option for refractory mucormycosis \[[@R13]-[@R15]\].

Despite the lack of well-designed trials assessing the efficacy and safety of this approach, combination antifungal regimens are widely used in real-life pediatric settings as reported by several studies. Monocentric surveys on IMI in immunocompromised children reported the use of combination therapy in a percentage of cases ranging from 32% to 92% \[[@R2]-[@R4]\]. A multicenter cohort study performed by Burgos et al, involving 6 US pediatric centers, reported the use of combination regimens in up to 80% of IMI \[[@R1]\]. Moreover, a multicenter international prospective cohort study on mucormycosis by Pana *et al* reported the use of first-line combination therapy in 53% of cases \[[@R6]\].

Similar to our findings, several pediatric series report the use of CAT mainly as salvage treatment \[[@R5], [@R16]-[@R19]\], but also as first-line, especially in patients receiving anti-mold prophylaxis \[[@R5]\].

In a recent Italian multicenter study on 127 invasive fungal infections in hemato-oncological pediatric patients, up to 45/126 (36%) episodes were treated with antifungal combinations as initial therapy and the author speculates that this choice was driven by the more severe clinical conditions of these patients \[[@R19]\]. Furthermore, in the international multicenter observational cohort study by Wattier et al on 131 IMI in children affected by hematological neoplasms, first-line combination therapy was used in 53% of cases and, similar to our findings, it was mainly used in patients who were already receiving anti-mold prophylaxis possibly due to concerns about prophylaxis-induced resistance \[[@R5]\].

Overall response to combination therapy in our case series was 69.2% with an IMI associated mortality of 15.4%, and no definitive discontinuations related to toxicity occurred.

Data from the pediatric literature on CAT report similar rates of favorable responses and toxicity, although the heterogeneity of patient populations and antifungal regimens of such studies, together with different underlying neoplasms and fungal infections included, prevent from drawing any evidence about the superiority of CAT over monotherapy in relation to outcome and safety \[[@R3], [@R16]-[@R18]\]. Indeed, outcomes reported in our case series are not different from outcomes reported in the literature in children treated with monotherapy, and overall there is paucity of well-designed studies aimed at comparing mortality in pediatric patients treated with monotherapy versus combination therapy.

In particular, only 1 prospective study from Wattier et al compared outcomes and safety of 131 children with IMI (75% IA) treated with CAT (70/131, 53%) or monotherapy (61/131, 47%) \[[@R5]\]. In that study, no favorable association between CAT and outcome was found; conversely, CAT was associated with increased toxicity. However, the study had several limitations, indeed acknowledged by the authors, in particular the heterogeneity of CAT. Furthermore, the ineffectiveness of CAT on the outcome was hampered by several confounding factors (with the more severely ill patients being more likely to receive more aggressive therapy but also being more likely to experience poor outcomes), and the association of CAT with toxicity could be a result of the underlying severity of the illnesses.

In our center, the combination of L-AMB with caspofungin was used for IA as the main CAT. This combination is synergic *in vitro* \[[@R20]\] and showed promising clinical results among both adults \[[@R12]\] and children \[[@R18]\]. All but 1 patient (4/5) treated with this association survived. The fifth died due to the progression of the underlying malignancy; of note, this patient was the only one in this group to have aspergillosis with rhino-cerebral involvement.

Conflicting results are available in the literature about the association of L-AMB with azoles. Some *in vitro* studies have reported antagonism between the 2 drugs \[[@R21]\] while this combination has proven to be effective and associated with improved outcomes in animal models of CNS aspergillosis \[[@R22]-[@R24]\]. Although evidence is controversial, many real-life studies report the use of this combination in clinical practice in the pediatric setting \[[@R4], [@R5], [@R19]\]. In our case series, the combination of L-AMB with voriconazole was mainly used to treat CNS aspergillosis. Among these patients, mortality rate was high: Of note, CNS aspergillosis is historically associated with poor outcome \[[@R13]\] and studies are needed to establish the best treatment.

The intrinsic resistance of *Fusarium* species to most antifungals leads to high mortality rates in patients with invasive fusariosis. Despite the concerns about *in vitro* antagonism between polyenes and azoles, some studies have shown *in vitro* synergism of voriconazole and L-AMB against *Fusarium* \[[@R25]\]. Based on such studies and on few clinical reports of success in the treatment of invasive fusariosis with the association of L-AMB with voriconazole, some authors support CAT for fusariosis \[[@R26]-[@R29]\]. In this case series 1 patient with invasive fusariosis was successfully treated with L-AMB associated with voriconazole.

Lastly, the association of L-AMB with caspofungin or posaconazole is associated with encouraging results in the salvage treatment of mucormycosis \[[@R14], [@R15]\]. We have described 2 cases of mucormycosis with rhino-cerebral and orbital involvement successfully treated with L-AMB in association with posaconazole and surgery. A recent study from Greece by Pana et al reported the use of CAT in 26/63 children with invasive mucormycosis \[[@R6]\]; however, the impact of CAT on survival could not be estimated due to the small patient population.

In the present age, cases of IMI in immunocompromised children affected by hematological malignancies are still associated with high morbidity and mortality. Through our case series we report our real-life experience in treating IMI with CAT at our pediatric center. Given the merely descriptive purpose of our report which lacks a statistical analysis, we are aware that our work will not provide enough evidence for further recommendations about efficacy and safety of CAT in children with hemato-oncological malignancies affected by IMI. However, given the scarcity of data about this topic in the literature together with the rarity of such infections in this patient population yet associated with a severe prognosis, we believe that even isolated experiences from single-center institutions can add useful knowledge to this field.

While waiting for well-designed controlled studies, CAT might be regarded as a possible approach for IMI in children with hemato-oncological diseases; in particular, the use of CAT could be considered early when prognosis is not favorable.
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